Structure-based discovery of potent and selective melatonin receptor agonists

Abstract

Melatonin receptors MT₁ and MT₂ are involved in synchronizing circadian rhythms and are important targets for treating sleep and mood disorders, type-2 diabetes and cancer. Here, we performed large scale structure-based virtual screening for new ligand chemotypes using recently solved high-resolution 3D crystal structures of agonist-bound MT receptors. Experimental testing of 62 screening candidates yielded the discovery of 10 new agonist chemotypes with sub-micromolar potency at MT receptors, with compound <b>21</b> reaching EC₅₀ of 0.36 nM. Six of these molecules displayed selectivity for MT₂ over MT₁. Moreover, two most potent agonists, including <b>21</b> and a close derivative of melatonin, <b>28</b>, had dramatically reduced arrestin recruitment at MT₂, while compound <b>37</b> was devoid of G_i signaling at MT₁, implying biased signaling. This study validates the suitability of the agonist-bound orthosteric pocket in the MT receptor structures for the structure-based discovery of selective agonists.